Zentalis Pharmaceuticals Llc (NASDAQ:ZNTL) — Market Cap & Net Worth
Market Cap & Net Worth: Zentalis Pharmaceuticals Llc (ZNTL)
Zentalis Pharmaceuticals Llc (NASDAQ:ZNTL) has a market capitalization of $195.77 Million ($195.77 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #16619 globally and #3757 in its home market, demonstrating a 5.14% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zentalis Pharmaceuticals Llc's stock price $4.09 by its total outstanding shares 70931016 (70.93 Million). Analyse Zentalis Pharmaceuticals Llc operating cash flow efficiency to see how efficiently the company converts income to cash.
Zentalis Pharmaceuticals Llc Market Cap History: 2020 to 2026
Zentalis Pharmaceuticals Llc's market capitalization history from 2020 to 2026. Data shows change from $3.68 Billion to $290.11 Million (-24.84% CAGR).
Index Memberships
Zentalis Pharmaceuticals Llc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.01% | #458 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1629 of 3165 |
Weight: Zentalis Pharmaceuticals Llc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Zentalis Pharmaceuticals Llc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zentalis Pharmaceuticals Llc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.19x
Zentalis Pharmaceuticals Llc's market cap is 3.19 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $214.92 Million | $67.42 Million | -$165.84 Million | 3.19x | N/A |
Competitor Companies of ZNTL by Market Capitalization
Companies near Zentalis Pharmaceuticals Llc in the global market cap rankings as of May 4, 2026.
Key companies related to Zentalis Pharmaceuticals Llc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Zentalis Pharmaceuticals Llc Historical Marketcap From 2020 to 2026
Between 2020 and today, Zentalis Pharmaceuticals Llc's market cap moved from $3.68 Billion to $ 290.11 Million, with a yearly change of -24.84%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $290.11 Million | +202.96% |
| 2025 | $95.76 Million | -55.45% |
| 2024 | $214.92 Million | -80.00% |
| 2023 | $1.07 Billion | -24.78% |
| 2022 | $1.43 Billion | -76.04% |
| 2021 | $5.96 Billion | +61.84% |
| 2020 | $3.68 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Zentalis Pharmaceuticals Llc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $195.77 Million USD |
| MoneyControl | $195.77 Million USD |
| MarketWatch | $195.77 Million USD |
| marketcap.company | $195.77 Million USD |
| Reuters | $195.77 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zentalis Pharmaceuticals Llc
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosert… Read more